Moderna Stuns Wall Street With Surprise Profit, Raises Outlook
Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.
Stocks · News reference
Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Moderna (MRNA) Q3 Earnings and Revenues Top Estimates
Moderna reported quarterly earnings of $0.38 per share, significantly beating the consensus estimate of a loss of $1.1 per share, with a 134.55% earnings surprise. The company posted revenues of $1.31 billion, surpassing estimates by 47.73%. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Moderna shares have gained 718.8% year-to-date, substantially outperforming the S&P 500's 7.4% gain.
Moderna, JFrog, TransMedics, Ubiquiti And Other Big Stocks Moving Higher On Friday
U.S. stocks rose, Nasdaq gained ~400 points. Moderna jumped 9.1% on strong Q3 results and higher FY26 guidance; other stocks rallied on results and deals.
Growth Lead Sectors In Friday Trading As Defensives Trail
Seven sectors are higher and four are lower in Friday’s regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
Moderna Just Gave Investors Yet Another Thing to Cheer About
Moderna reported a surprise profitable quarter with $1.31B in revenue (29% YoY growth) and $0.38 EPS, defying analyst expectations of a loss. The company raised full-year guidance and ended with $8.1-8.3B in cash. Its cancer vaccine with Merck showed strong Phase 3 results, reducing melanoma recurrence risk by 42%, while the stock has surged 720% in 2026. However, risks include COVID vaccine sales volatility and significant optimism already priced into the stock.
Align Technology Announces $270 Million Accelerated Stock Repurchase Agreement
Align Technology, Inc. has entered into an accelerated stock repurchase agreement with Goldman Sachs & Co. LLC to repurchase $270 million of its common stock.